Introduction {#s0005}
============

Hepatocellular carcinoma (HCC) is an important cause of death worldwide [@b0005; @b0010]. It is the sixth most common cancer worldwide and the third cause of cancer death [@b0015]. It kills more than 650,000 people around the world annually [@b0020]. Incidence of HCC has risen over the last 5--8 years with no significant change in the survival rate in the last two decades [@b0025].

In Egypt, Liver malignancies constitute 11.75% of the malignancies of the digestive organs and 1.6% of total malignancies. HCC ranks number one with an incidence rate of 70.48% [@b0030].

The etiology of HCC differs according to geographic, economic, and health status. The most common causes are alcohol consumption [@b0035], hepatitis C and B viruses [@b0040] and chronic necro-inflammatory hepatic disease. Commonly cirrhosis is present in 60--80% of patients with HCC [@b0045]. Among Egyptian patients HCV and HBV infections are the most common risk factors for HCC. About 10% -- 20% of the general Egyptian population is infected with HCV [@b0050]. Approximately 90% of Egyptian HCV isolates belong to subtype (4a) which responds less successfully to interferon therapy than other subtypes [@b0055]. Most of the HCC occurs in cirrhotic patients associated with viral infection. However, 10--25% of cases develop in absence of cirrhosis. This is due to the direct oncogenic effect of HBV as HBV-DNA genome integrates in hepatocellular chromosomes [@b0060]. In contrast HCV exerts its carcinogenic effect probably through production of cirrhosis [@b0065]. Many studies showed that HCV has a direct oncogenic action through its core component [@b0070].

All these facts made it essential to find sensitive markers for early diagnosis and monitoring of recurrence of HCC [@b0075].

Ultrasound examination of the liver and detection of AFP level in serum are commonly used to screen for liver cancer [@b0080]. Although detection of AFP level is easy and less expensive, but it shows less sensitivity [@b0085], since elevation in AFP level is common in patients with chronic liver disease, pregnancy and germ cell tumors. AFP titers also rise with flares of active hepatitis, and may be persistently elevated in patients with cirrhosis [@b0090]. Ultrasound is better, but is more expensive, operator dependent and less reliable in the presence of cirrhosis [@b0095]. Thus, new markers with high sensitivity and specificity are required.

Prothrombin induced by vitamin K absence-II (PIVKA-II) is also known as Des-gamma carboxyprothrombin (DCP) is an abnormal prothrombin protein that is increased in the sera of patients with HCC. Generation of (PIVKA-II) is thought to be a result of an acquired defect in the post-translational carboxylation of the prothrombin precursor in malignant cells [@b0100]. The validity of PIVKA-II as a tumor marker for HCC patients has been reported by many investigators [@b0105; @b0110; @b0115]. None of the known markers are optimal, however when used together their sensitivity increases [@b0120; @b0125].

The present study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its sensitivity and specificity as compared with the usual recommended marker AFP.

Patients and methods {#s0010}
====================

This study was conducted on 72 patients and 11 apparently healthy individuals as control. Patients were initially subjected to complete clinical examination and abdominal ultrasonography. Blood samples were collected for complete blood picture, liver and kidney function tests, Fasting blood sugar, serum potassium and sodium levels using the standard laboratory methods [@b0130]. Hepatitis markers HBs Ag, HBs Ab, HBc Ag and HCV Ab were detected using ELISA technique, HCV-RNA by qualitative PCR. Diagnosis of HCC was confirmed by triphasic CT scan or liver biopsy guided by U/S. Serum was collected and stored at −70 °C until assayed. Level of serum AFP was detected using ELISA technique (RADIM SpA, Italy) and PIVKA-II level in the plasma using ELISA kit (Stago Diagnostic, France).

Patients with cholangiocarcinoma, hepatoblastoma, hemangioma, or any other hepatic tumor rather than HCC and metastasizing to the liver were excluded from the study. The diagnosis was confirmed by abdominal ultrasound, triphasic CT scan of the abdomen and tissue biopsies for histopathological examinations. HCC's patients were classified according to Barcelona criteria [@b0135], and patients with liver cirrhosis were classified according to Child- Pugh criteria [@b0140].

The study was approved by the Ethical Committee of National Cancer Institute (NCI), Cairo University, which conforms to the code of ethics of the World Medical Association (Declarations of Helsinki). The study was explained to all individuals who were also informed with a written consent. Individuals were divided into three groups; group I (Control) consisted of 11 apparently healthy subjects, matched with patient's age and sex. Group II included patients who had history of HCV infection that was confirmed by laboratory findings. This group consisted of 24 patients, 17 of them were males and seven were females. Their median age was 51.5 years (33--70), half of them with cirrhosis. Group III Consisted of 48 patients with HCC who attended NCI clinic, Cairo University during the years 2007 to 2009. Thirty four were males and 14 females. Their median age was 59.5 years (38--77) ([Table 1](#t0005){ref-type="table"}). A 52.1% of them were cirrhotic, 10 patients were Child A (20.8%), 33 Child B (68.8%) and five were Child C (10.4%). Patients were classified according to the Barcelona Clinic Liver Cancer" (BCLC) system into18 patients stage A (37.5%), seven patients stage B (14.6%), 18 patients stage C (37.5%) and five patients stage D (10.4%) [Table 5](#t0025){ref-type="table"}. Patients were also classified according to their clinic-pathological features including stage, grade and size of tumor.

Statistical analysis {#s0015}
--------------------

Continuous variables were expressed as median (range) and were compared by using nonparametric (Mann--Whitney test) for two groups comparison and Kruskall--Wallis test for multiple group comparison. The ROC (receiver operator characterizing) curve was drawn, to improve the specificity and sensitivity of the studied parameters. The analysis was performed using SPSS, version 14.

Results {#s0020}
=======

This study was conducted on 72 patients and 11 apparently healthy individuals serving as control. Demographic characteristics, Clinic-pathological and laboratory investigations of individuals in different investigated groups are presented in [Tables 1 and 2](#t0005 t0010){ref-type="table"},

On comparing AFP and PIVKA-II levels in HCV patients to the control group there was no significant statistical difference. However, significant elevation was observed in HCC group when compared with control and HCV groups as illustrated in [Table 3](#t0015){ref-type="table"}.

AFP was significantly higher in patients with HCV associated with cirrhosis. However, in HCC patients AFP level was not significantly affected by presence of cirrhosis. While PIVKA-II level was not significantly affected with presence of cirrhosis in HCV and HCC patients, results are illustrated in [Table 4](#t0020){ref-type="table"}.

AFP level showed no significant changes when measured in different grades and stages of HCC. On the other hands, PIVKA-II level showed gradual increase with grade and stage. This increase was statistically significant when comparing all grades and stages, except when comparing stage 1 with stage 2 as shown in [Table 5](#t0025){ref-type="table"}.

PIVKA-II level showed significant increase with higher BCLC stages with a *p*-value less than 0.001, however this was not obvious with AFP level (*p* = 0.292), results are illustrated in [Table 6](#t0030){ref-type="table"}.

AFP level showed no significant changes between HCC subclasses with or without lymph nodes involvement, splenomegaly or portal vein thrombosis. However, PIVKA-II level was significantly higher in subgroups with any of those lesions [Table 7](#t0035){ref-type="table"}.

AFP showed no significant changes in its level when measured in tumors with size less than 3 cm, size from 3 to 5 cm or tumors more than 5 cm. On the other hand, PIVKA-II showed gradual and significant increase correlating with the size of tumor [Table 8](#t0040){ref-type="table"}.

Multiple receiver operating characteristic curve (ROC) was drawn to evaluate validity of both AFP and PIVKA-II based on the distribution of HCC patients according to tumor size. As shown in [Fig. 1](#f0005){ref-type="fig"}A; comparison between HCC patients with tumor size \<3 and 3--5 revealed sensitivity and specificity 73.3%, 75% respectively for AFP, and 100% for PIVKA-II with a cut-off value of AFP and PIVKA-II \>22.31 and \>39.6 ng/mL respectively. On the other hand, comparison between the HCC patients with tumor size 3--5 and \>5 revealed sensitivity and specificity 44%, 73.30%, respectively for AFP, and 100% for PIVKA-II with a cut-off value of AFP and PIVKA-II \>28 and \>53.7 ng/mL respectively as shown in [Fig. 1](#f0005){ref-type="fig"}B.

Discussion and conclusion {#s0025}
=========================

HCC is a leading cause of mortality among patients with cirrhosis [@b0145]. Detection of HCC at early stages is critical for good clinical outcome as the prognosis of HCC patients is very poor when diagnosed at late stages [@b0150; @b0155].

Although serum AFP is the most established tumor marker in HCC and considered as the golden standard to which other markers are compared, it was found to be normal in about 30% of the patients, especially in early stages [@b0150; @b0155]. Elevated levels might be seen in patients with cirrhosis or exacerbation of chronic hepatitis [@b0160; @b0165]. Ultrasonography an important tool for diagnosis of HCC however it depends on the operator's experience [@b0170; @b0175]. Accordingly the validity of other biomarkers in diagnosis of HCC including PIVKA-II needs to be investigated.

The present work was designed to study the impact of PIVKA-II on early diagnosis of HCC and to correlate it with different clinic-pathological features of the disease, as compared with AFP. The ultimate goal is to diagnose HCC at early stage.

The present study revealed significant male predominance; males represented 70.8% of all patients in HCC group, with 83.3% of patients over 50 years. These findings are consistent with Bressac et al. [@b0180], Bosch et al. [@b0065] and Parkin et al. [@b0185]. Male predominance can be explained by more hepatitis carrier states, exposure to environmental toxins and hepatic effect of androgens [@b0190].

Our results revealed a significant elevation of PIVKA-II and AFP levels in HCC group compared to control and HCV groups. PIVKA-II showed more increase than AFP level in malignant compared to benign liver diseases. These results could be explained in view of the findings of Okuda et al. [@b0195] who demonstrated that there is excessive synthesis of prothrombin precursors by human HCC tissues, which might contribute to production of PIVKA-II, rendering the latter a useful marker for HCC with a very high specificity. These results were consistent with those of Marrero et al. [@b0115] who reported that PIVKA-II is more sensitive than AFP for differentiating HCC from other benign liver diseases.

No significant changes were observed in serum level of AFP among different grades of HCC. On the other hand, plasma level of PIVKA-II showed significant gradual elevation correlating with progressive disease grade. AFP level was not affected by tumor size. However, plasma PIVKA-II level increased in correlation with tumor size to reach its maximum level for tumors with sizes more than 5 cm. These findings were consistent with those of Gotoh et al. [@b0200], El-Assaly et al. [@b0205] and Durazo et al. [@b0210] who reported that PIVKA-II levels significantly correlate with histopathological grade of HCC and size of solitary tumors, being 25 times higher in tumors more than 2 cm, compared to those less than 2 cm. AFP showed no significant correlations with the stage of HCC. In contrary PIVKA-II showed gradual increase in its level with increase of disease stage. These findings were also consistent with those reported by Nagaoka et al. [@b0215], and Kaibori et al. [@b0220]. Beak et al. [@b0225] demonstrated that PIVKA-II is more accurate than AFP for diagnosis of HCC. PIVKA-II was positive in 96%, 93% and 74% in patients with tumor size larger than 5, 3--5, and less than 3 cm while AFP was positive in 65%, 57% and 48% respectively.

In the present study, PIVKA-II levels showed significant elevation in HCC patients with portal vein thrombosis, while AFP level was not affected. These findings were consistent with those of El-Assaly et al. [@b0200]. Gotoh et al. [@b0205] also reported that PIVKA-II is better than AFP in reflecting invasive characteristics of HCC, especially invasion of extra and intrahepatic venous branches.

Same results were obtained in the present study concerning the levels of PIVKA-II and AFP for HCC patients with or without lymph node metastasis. These results were consistent with Baek et al. [@b0225] who reported that PIVKA-II level increased with tumor burden and metastasis.

The present study revealed a significant elevated level of PIVKA-II in cases of HCC associated with hepatosplenomegaly 112.7 (95% CI; 51.83--173.57) compared to 43.24 (95% CI 34.9--51.58)in patients with no hepatosplenomegaly. These data are consistent with that of Bae et al. who reported that patients with a PIVKA-II production ⩾300 mAU/mL had a 2.7-fold (95% confidence interval; 1.5--4.8; *P* \< 0.001) and 3.7-fold (95% confidence interval; 2.0--6.6; *P* \< 0.001) increased risk for extrahepatic metastases after adjustment for stage, platelet count, alpha-fetoprotein ⩾400 ng/mL, and portal vein thrombosis according to the AJCC and BCLC staging systems, respectively [@b0230].

ROC curve was drawn to compare between both markers depending on the tumor size and to determine the best cut-off value. The results revealed that, the comparison between tumor size \<3 and 3--5 cm by using the best cut-off value of AFP (\>22.31) shows sensitivity (73.3%) and specificity (75%). While for PIVKA-II (\>39.6) it shows sensitivity (100%) and specificity (100%). Moreover, the pair wise comparison of both AFP and PIVKA-II show extremely high significance (\<0.001). Different sensitivities and specificities from 62% to 95% and 53.3% to 98% were reported by other authors [@b0115; @b0235; @b0240]. In a meta-analysis based on literature review of 20 publications, the overall sensitivity, specificity of DCP was 67% (95%CI, 58--74%), 92% (95%CI, 88--94%) respectively. [@b0245] In a study conducted by Bertino et al. serum DCP was found to have a sensitivity ranging from 48% to 62%, a specificity of 81--98%. [@b0250], these variations may be attributed to variation of the sample size, tumor size or number of masses in different studies.

In conclusion the present study reveals that PIVKA-II is superior to AFP in discrimination between HCC and other benign liver diseases. Furthermore, PIVKA-II can be used to differentiate between different histopathological stages and grades of HCC, and to evaluate portal vein thrombosis. The high sensitivity and specificity of PIVKA-II may give it value in screening high risk population and diagnose the disease at early stages when curative treatments are possible.
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###### 

Demographic characteristics of the three groups of patients.

  Parameter         Control       HCV            HCC
  ----------------- ------------- -------------- ------------
  Sample size       11            24             48
  Median age        34            51.5           59.5
  Range             29--52        33--70         38--77
                                                 
  *Sex*                                          
  Males *n* (%)     7 (63.63%)     17 (70.83%)   34 (70.8%)
  Females *n* (%)   4 (36.36%)    7 (29.16%)     14 (29.25)

Values are expressed as medians (ranges) for age, and as number (percentage) for sex.

###### 

Comparison of laboratory investigations of individuals in the three groups.

  Parameter                                            Control (n = 11)      HCV (n = 24)                          HCC (n = 48)
  ---------------------------------------------------- --------------------- ------------------------------------- -------------------------------------
  AST (up to 40 U/I)                                   21 (17--25)           55.5 (28--83)                         73.5 (8--322)
  vs. control                                                                0.045                                 \<0.001
  vs. HCV                                                                                                          0.003
  ALT (up to 55 U/I)                                   26 (22--29)           50 (18--93)                           56 (10.2--170)
  vs. control                                                                NS[⁎](#tblfn1){ref-type="table-fn"}   \<0.001
  vs. HCV                                                                                                          NS[⁎](#tblfn1){ref-type="table-fn"}
  Alk. phosphatase (61--190 U/l)                       120 (100--175)        167 (125--230)                        252 (134--868)
  vs. control                                                                NS[⁎](#tblfn1){ref-type="table-fn"}   \<0.001
  vs. HCV                                                                                                          \<0.001
  direct bilirubin (up to 0.25 mg/dL)                  0.15 (0.1--0.19)      1.8 (1.2--2.4)                        1.2 (0.7--2)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          \<0.001
  Total bilirubin (up to 1 mg/dL)                      0.7 (0.42--0.8)       2.8 (1.5--3.5)                        1.7 (0.4--7.7)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          NS[⁎](#tblfn1){ref-type="table-fn"}
  GGT (up to 55 IU/l)                                  32 (18--39)           53.7 (32.2--70.9)                     74.7 (59.5--89.6)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          \<0.001
  Creatinine (0.5--1.4 mg/dL)                          0.8 (0.5--1.2)        0.96 (0.7--1.6)                       0.7 (0.2--2.4)
  vs. Control                                                                NS[⁎](#tblfn1){ref-type="table-fn"}   NS[⁎](#tblfn1){ref-type="table-fn"}
  vs. HCV                                                                                                          NS
  Urea g/dL (10--50 mg/dL)                             17 (13--21)           39.7 (30.2--49.5)                     36 (27.8--49.5)
  vs. Control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          NS[⁎](#tblfn1){ref-type="table-fn"}
  Albumin (3.5--5 g/dL)                                4.1 (3.8--4.4)        2.65 (1.5--4.1)                       3.05 (1.8--4.2)
  vs. Control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          0.022
  Globulin g/dL (2.3--3.5 g/dL)                        3.5 (2.7--4.3)        3.75 (2.3--5.2)                       4.6 (2.9--6.3)
  vs. Control                                                                NS[⁎](#tblfn1){ref-type="table-fn"}   NS[⁎](#tblfn1){ref-type="table-fn"}
  vs. HCV                                                                                                          NS[⁎](#tblfn1){ref-type="table-fn"}
  Total protein (6.4--8.2 g/dL)                        7.6 (6.9--8.2)        6.9 (6.2--7.4)                        7.2 (6.5--8.2)
  vs. Control                                                                \<0.001                               0.01
  vs. HCV                                                                                                          0.001
  Albumin/Globulin ratio (1--1.5)                      1.22 (0.884--1.556)   0.992 (0.288--1.696)                  0.724 (0.286--1.448)
  vs. Control                                                                \<0.001                               0.004
  vs. HCV                                                                                                          NS[⁎](#tblfn1){ref-type="table-fn"}
  Prothrombin time (12--15 s)                          13.8 (13--14.7)       16.6 (13--17.9)                       17.4 (14.9--22)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          \<0.001
  Prothrmbin concentration (80--100%)                  85 (79--100)          71.4 (62.5--100)                      65.5 (52.6--77)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          \<0.001
  International Normalization Ratio (INR) (0.8--1.2)   1.1 (1--1.2)          1.4 (1--1.6)                          1.51 (1.24--1.9)
  vs. control                                                                \<0.001                               \<0.001
  vs. HCV                                                                                                          \<0.001

Results are expressed as medians (range); *P*-value is set at 0.05.

Statistical test; Mann--Whitney *U* test.

Not significant.

###### 

Comparison of Medians and ranges for level of AFP and PIVKA-II of individuals in different investigated groups.

                            Control    HCV          HCC
  ------------------------- ---------- ------------ -------------
  Sample size               11         24           48
  Median AFP (ng/mL)        2.3        14.6         64.6
  Range                     1--3.6     1.46--68.8   2.7--695
  vs. control                          0.734        0.002
  vs. HCV                                           \<0.001
  Median PIVKA-II (ng/mL)   1          2.7          59.5
  Range                     0.6--1.5   1.2--3.5     29.8--192.4
  vs. control                          0.928        \<0.001
  vs. HCV                                           \<0.001

Values are expressed as median (range); *P*-value using is set at 0.05.

Statistical test: Mann--Whitney *U* for comparing HCC against HCV and control, and HCV against control.

###### 

Comparison of median Level of AFP and PIVKA-II in HCC and HCV patients based on cirrhosis.

  Group       AFP         PIVKA-II                  
  ----------- ----------- ----------- ------------- -----------
  *HCV*                                             
  *N*         12          12          12            12
  Median      8.7         24.4        2.4           2.9
  Range       3.2--68.8   1.5--29.9   2.7--3.5      1.2--2.6
  *P*-value   0.005       \<0.001                   
                                                    
  *HCC*                                             
  *N*         23          25          23            25
  Median      120         34          130.1         53.7
  Range       2.7--606    6.3--695    29.8--192.4   36--191.4
  *P*-value   0.942       0.386                     

Results are expressed as median (range); *P*-value using is set at 0.05.

Statistical test: Mann--Whitney *U*.

###### 

AFP and PIVKA-II level in different grades and stages of HCC patients.

  HCC subdivisions   Sample size   AFP                  *P*-value     PIVKA-II               *P*-value
  ------------------ ------------- -------------------- ------------- ---------------------- -----------------
  Grade I            15            125.8 (2.7--248.9)   *P* = 0.088   39.6 (29.8--43.6)      *P* \< 0.001
  Grade II           14            350.65 (6.3--695)                  52.7 (42.3--89.2)      
  Grade III          13            242.95 (5.9--480)                  145.8 (120.7--191.4)   
  Grade IV           6             269.5 (120--419)                   191.9 (180.5--192.4)   
  Stage 1            8             11.65 (2.7--20.6)    *P* = 0.232   36.75 (29.8--39.6)     *P*~2~ = NS^∗^
                                                                                             *P*~3~ \< 0.001
                                                                                             *P*~4~ \< 0.001
  Stage 2            15            349.4 (3.8--695)                   43.6 (40--53.7)        *P*~1~
                                                                                             *P*~3~ = 0.002
                                                                                             *P*~4~ = 0.003
  Stage 3            17            305.95 (5.9--606)                  130 (54.9--180.5)      *P*~1~ \< 0.01
                                                                                             *P*~2~ \< 0.01
                                                                                             *P*~4~ \< 0.001
  Stage 4            8             246.5 (13--480)                    191.4 (186.2--192.4)   *P*~1~ \< 0.001
                                                                                             *P*~2~ \< 0.001
                                                                                             *P*~3~ \< 0.001

Results are expressed as median (range); *P*-value using is set at 0.05.

*P*~1~ stands for Stage 1.

*P*~2~ stands for Stage 2.

*P*~3~ stands for Stage 3.

*P*~4~ stands for Stage 4.

∗Not significant.

###### 

Comparison of AFP and PIVKA-II level in different grades and stages of HCC patients.

  HCC subdivisions   Sample size   AFP (ng/mL)          *P*-value     PIVKA-II (ng/mL)       *P*-value
  ------------------ ------------- -------------------- ------------- ---------------------- ----------------------------------------------
  Grade I            15            125.8 (2.7--248.9)   *P* = 0.088   39.6 (29.8--43.6)      *P* \< 0.001
  Grade II           14            350.65 (6.3--695)                  52.7 (42.3--89.2)      
  Grade III          13            242.95 (5.9--480)                  145.8 (120.7--191.4)   
  Grade IV           6             269.5 (120--419)                   191.9 (180.5--192.4)   
  Stage 1            8             11.65 (2.7--20.6)    *P* = 0.232   36.75 (29.8--39.6)     *P*~2~ = NS[⁎](#tblfn2){ref-type="table-fn"}
                                                                                             *P*~3~ \< 0.001
                                                                                             *P*~4~ \< 0.001
  Stage 2            15            349.4 (3.8--695)                   43.6 (40--53.7)        *P*~1~
                                                                                             *P*~3~ = 0.002
                                                                                             *P*~4~ = 0.003
  Stage 3            17            305.95 (5.9--606)                  130 (54.9--180.5)      *P*~1~ \< 0.01
                                                                                             *P*~2~ \< 0.01
                                                                                             *P*~4~ \< 0.001
  Stage 4            8             246.5 (13--480)                    191.4 (186.2--192.4)   *P*~1~ \< 0.001
                                                                                             *P*~2~ \< 0.001
                                                                                             *P*~3~ \< 0.001
  BCLC A             18            348.8 (2.7--695)     *P* = 0.292   41.75 (29.8--53.7)     *P* = 0.001
  B                  7             306.15 (6.3--303)                  110.25 (40--180.5)     
  C                  18            257.45 (5.9--509)                  112 (51.7--192.4)      
  D                  5             58.5 (12--105)                     93.5 (40.2--146.8)     

Results are expressed as median (range); *P*-value using is set at 0.05.

Statistical test: Kruskall--Walles for comparison of grades and BCLC stage.

Mann--Whitney-*U* for comparison of stage.

*P*~1~ stands for Stage 1.

*P*~2~ stands for Stage 2.

*P*~3~ stands for Stage 3.

*P*~4~ stands for Stage 4.

Not significant.

###### 

Comparison of median level of AFP and PIVKA-II in HCC patients based on metastasis to lymph node, splenomegaly and portal vein thrombosis.

  HCC subdivisions                 Number   AFP                 *P*-value                             PIVKA-II             *P*-value
  -------------------------------- -------- ------------------- ------------------------------------- -------------------- --------------
  Without lymph node metastasis    36       348.85 (2.7--695)   NS[⁎](#tblfn3){ref-type="table-fn"}   45.4 (29.8--146.8)   *P* \< 0.001
  With lymph node metastasis       12       244 (8--480)        188.2 (65.2--192.4)                                        
  Without splenomegaly             14       348.85 (2.7--695)   NS[⁎](#tblfn3){ref-type="table-fn"}   47 (29.8--64.3)      *P* \< 0.001
  With splenomegaly                34       256.25 (3.5--509)   112.65 (32.9--192.4)                                       
  Without portal vein thrombosis   22       348.85 (2.7--695)   NS[⁎](#tblfn3){ref-type="table-fn"}   59.5 (29.8--89.2)    *P* \< 0.001
  With portal vein thrombosis      26       257.45 (5.9--509)   1114.2 (36--192.4)                                         

Results are expressed as median (range); *P*-value using is set at 0.05.

Statistical test: Mann--Whitney *U* test.

Not significant.

###### 

Comparison of median level of AFP and PIVKA-II based on tumor size.

                         Tumor size                                         
  ---------------------- ------------ ------------------------------------- -------------------------------------
  Sample size            8            15                                    25
  Median AFP             104.35       349.4                                 305.95
  Range                  2.7--206     3.8--695                              5.9--606
  *p*-value                           NS[⁎](#tblfn4){ref-type="table-fn"}   NS[⁎](#tblfn4){ref-type="table-fn"}
  Median PIVKA-II        34.7         46.85                                 123.6
  Range                  29.8--39.6   40--53.7                              54.9--192.4
  *p*-value vs. \<3 cm                NS[⁎](#tblfn4){ref-type="table-fn"}   \<0.001
  vs. 3--5 cm                                                               \<0.001

Results are expressed as median (range); *P*-value using is set at 0.05.

Statistical test: Kruskall--Wallis test for comparison of three groups, and Mann--Whitney test for comparison between each two groups.

Not significant.
